Therapeutic uses of cannabigerol

Research output: Patent

Abstract

The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CB1 and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
Original languageEnglish
Patent numberWO2009001081
IPCA61K31/352; A61K36/185; A61P25/28; (+3)
Publication statusPublished - 31 Dec 2008

Fingerprint

Therapeutic Uses
Brain Injuries
Cannabinoid Receptor CB2
Cannabinoid Receptor CB1
Cachexia
Cannabinoids
Nephritis
Kidney Neoplasms
Movement Disorders
Psoriasis
Crohn Disease
Neurodegenerative Diseases
Glaucoma
Systemic Lupus Erythematosus
Nausea
Autoimmune Diseases
Osteoporosis
Vomiting
Rheumatoid Arthritis
Hypersensitivity

Cite this

Pertwee, R. G. (2008). IPC No. A61K31/352; A61K36/185; A61P25/28; (+3). Therapeutic uses of cannabigerol. (Patent No. WO2009001081).

Therapeutic uses of cannabigerol. / Pertwee, Roger Guy (Inventor).

IPC No.: A61K31/352; A61K36/185; A61P25/28; (+3). Patent No.: WO2009001081.

Research output: Patent

Pertwee, RG 2008, Therapeutic uses of cannabigerol, Patent No. WO2009001081, IPC No. A61K31/352; A61K36/185; A61P25/28; (+3).
Pertwee RG, inventor. Therapeutic uses of cannabigerol. A61K31/352; A61K36/185; A61P25/28; (+3). 2008 Dec 31.
Pertwee, Roger Guy (Inventor). / Therapeutic uses of cannabigerol. IPC No.: A61K31/352; A61K36/185; A61P25/28; (+3). Patent No.: WO2009001081.
@misc{5a9e10b6f51347649f09c6a7b6c5465b,
title = "Therapeutic uses of cannabigerol",
abstract = "The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CB1 and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.",
author = "Pertwee, {Roger Guy}",
year = "2008",
month = "12",
day = "31",
language = "English",
type = "Patent",
note = "WO2009001081; A61K31/352; A61K36/185; A61P25/28; (+3)",

}

TY - PAT

T1 - Therapeutic uses of cannabigerol

AU - Pertwee, Roger Guy

PY - 2008/12/31

Y1 - 2008/12/31

N2 - The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CB1 and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.

AB - The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CB1 and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.

M3 - Patent

M1 - WO2009001081

ER -